Smaller and Denser Speech Graphs in Nondemented Patients with Progressive Supranuclear Palsy
Table 1
Demographic and clinical features and neuropsychological measures of patients and healthy controls (means, standard deviations, and group differences).
Features/measures
PSP-RS ()
PD ()
Healthy controls ()
Group differences ( values)
Male : female
16 : 13
17 : 21
26 : 25
0.845
Age (years)
61.9 (6.2)
60.4 (7.1)
60.4 (6.9)
0.607
Education (years)
10.7 (3.0)
11.3 (2.9)
11.8 (2.1)
0.197
Motor symptoms
MDS-UPDRS III: motor examination
27.5 (10.6)
23.4 (12.2)
—
0.162
Hoehn and Yahr Scale
2.4 (0.6)
2.1 (0.8)
—
0.125
Disease duration (years)
1.4 (2.1)
2.0 (2.0)
—
0.202
Duration of motor symptoms (years)
2.7 (2.1)
3.5 (2.5)
—
0.179
Levodopa equivalent daily dose (mg/day)
332.8 (259.2)
320.6 (275.1)
—
0.855
Non-motor functions
Non-motor Symptoms Scale
36.5 (24.5)
26.6 (21.6)
—
0.172
Beck Depression Inventory-II
3.4 (2.0)
3.0 (2.0)
2.4 (1.8)
0.074
REM Sleep Behaviour Disorder Screening Questionnaire
1.8 (1.0)a
3.8 (1.4)b
2.1 (2.1)
0.001
Epworth Sleep Scale
4.7 (5.1)
4.2 (3.9)
3.1 (2.0)
0.165
Montreal Cognitive Assessment
23.5 (2.1)b
24.3 (2.6)b
27.9 (1.4)
<0.001
Note: PSP-RS: progressive supranuclear palsy-Richardson’s syndrome; PD: Parkinson’s disease; MDS-UPDRS: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale. Group differences, values of one-way ANOVAs or the Kruskal-Wallis one-way ANOVAs as appropriate. Asterisks (), a significant difference (two-tailed, , Bonferroni’s correction for thirteen tests). Post hoc two-sample -tests, .aCompared with patients with PD. bCompared with healthy controls.
